UB Paderborn / Katalog / Suche / in CDI

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet (British edition), 2016-05, Vol.387 (10032), p.2008-2016

2016

Link zum Volltext

Verfügbarkeit prüfen

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

Journal of clinical pharmacology, 2013-05, Vol.53 (5), p.491-504

2013

Link zum Volltext

Verfügbarkeit prüfen

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

The lancet oncology, 2007-11, Vol.8 (11), p.975-984

2007

Link zum Volltext

Verfügbarkeit prüfen

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy

Science translational medicine, 2012-06, Vol.4 (140), p.140ra86

2012

Link zum Volltext

Verfügbarkeit prüfen

Sunitinib efficacy against advanced renal cell carcinoma

The Journal of urology, 2007-11, Vol.178 (5), p.1883

2007

Link zum Volltext

Verfügbarkeit prüfen

A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer

Urologic oncology, 2013-07, Vol.31 (5), p.581-588

2013

Link zum Volltext

Verfügbarkeit prüfen

first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

Cancer chemotherapy and pharmacology, 2011-02, Vol.67 (2), p.447-454

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression

The Prostate, 2014-05, Vol.74 (7), p.792-803

2014

Link zum Volltext

Verfügbarkeit prüfen

Endothelin Receptor Antagonists in Cancer Therapy

Cancer investigation, 2007-12, Vol.25 (8), p.785-794

2007

Link zum Volltext

Verfügbarkeit prüfen

Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer

Urologic oncology, 2013-02, Vol.31 (2), p.211-218

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer

The Journal of urology, 2006-08, Vol.176 (2), p.500

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

Cancer chemotherapy and pharmacology, 2002-12, Vol.50 (6), p.465-472

2002

Link zum Volltext

Verfügbarkeit prüfen

A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer

Urologic oncology, 2013-05, Vol.31 (4), p.436-441

2013

Link zum Volltext

Verfügbarkeit prüfen

DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water

Analytical biochemistry, 1990-11, Vol.191 (1), p.31-34

1990

Link zum Volltext

Verfügbarkeit prüfen

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

The lancet oncology, 2006-06, Vol.7 (6), p.472-479

2006

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Cancer chemotherapy and pharmacology, 2009-06, Vol.64 (1), p.79-86

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group

Urologic oncology, 2009-09, Vol.27 (5), p.496-501

2009

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Investigational new drugs, 2012-04, Vol.30 (2), p.794-802

2012

Link zum Volltext

Verfügbarkeit prüfen

Expression of spermidine/spermine N 1 ‐acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis

The Prostate, 2015-08, Vol.75 (11), p.1150-1159

2015

Link zum Volltext

Verfügbarkeit prüfen

Prostate cancer cells survive anti‐androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities

The Prostate, 2021-09, Vol.81 (12), p.799-811

2021

Link zum Volltext

Verfügbarkeit prüfen

Expression of spermidine/spermine N(1) -acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis

The Prostate, 2015-08, Vol.75 (11), p.1150-1159

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802

Medical oncology (Northwood, London, England), 2012-06, Vol.29 (2), p.761-767

2012

Link zum Volltext

Verfügbarkeit prüfen

Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma

Cancer Immunology, Immunotherapy, 2011-10, Vol.60 (10), p.1447-1460

2011

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy

Sunitinib efficacy against advanced renal cell carcinoma

A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer

first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression

Endothelin Receptor Antagonists in Cancer Therapy

Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer

Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer

DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Expression of spermidine/spermine N 1 ‐acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis

Prostate cancer cells survive anti‐androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities

Expression of spermidine/spermine N(1) -acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802

Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma

Aktive Filter

Suchergebnisse filtern